美国45岁及以下成人HPV疫苗接种的成本效果:简化传播模型估算
研究采用简化动态数学模型,评估美国将9价HPV疫苗项目扩展至27至45岁「中年成人」的增量成本与收益。结果显示,常规接种12至26岁女性和12至21岁男性的成本低于每获得一个QALY花费1万美元;结论认为中年成人接种的成本效果远低于青少年常规接种加女性至26岁、男性至21岁的补种策略。
要点
- 青少年常规接种加年轻成人补种极具成本效果,每QALY低于1万美元。
- 中年成人接种成本效果远低于青少年常规接种加年轻成人补种策略。
核心结论
- 中年成人HPV疫苗接种的成本效果远低于对所有11至12岁青少年常规接种及女性至26岁、男性至21岁补种的比较策略。
研究设计与样本
- 研究改编已发表的HPV传播与疾病动态数学模型,估算9价HPV疫苗项目扩展至12至45岁人群相对于女性12至26岁、男性12至21岁项目的增量成本与收益。
主要发现
- 女性12至26岁、男性12至21岁9价HPV疫苗项目相比不接种,每获得一个QALY成本低于1万美元。
- 结果对中年成人HPV发病率、当前和历史接种覆盖率、疫苗价格及HPV疾病对生活质量影响的假设最为敏感。
临床怎么用
- 优先保障青少年常规接种和年轻成人补种,以维持高成本效果。
- 评估中年成人接种时需考虑其成本效果显著低于青少年策略。
局限性
- 结果基于简化传播模型,对中年成人HPV发病率、接种覆盖率、疫苗价格及生活质量影响等假设敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The objective of this study was to assess incremental costs and benefits of a human papillomavirus (HPV) vaccination program expanded to include "mid-adults" (adults aged 27 through 45 years) in the United States. METHODS: We adapted a previously published, dynamic mathematical model of HPV transmission and HPV-associated disease to estimate the incremental costs and benefits of a 9-valent HPV vaccine (9vHPV) program for people aged 12 through 45 years compared to a 9vHPV program for females aged 12 through 26 years and males aged 12 through 21 years. RESULTS: A 9vHPV program for females aged 12 through 26 years and males aged 12 through 21 years was estimated to cost < $10,000 quality-adjusted life year (QALY) gained, compared to no vaccination. Expanding the 9vHPV program to include mid-adults was estimated to cost $587,600 per additional QALY gained when including adults through age 30 years, and $653,300 per additional QALY gained when including adults through age 45 years. Results were most sensitive to assumptions about HPV incidence among mid-adults, current and historical vaccination coverage, vaccine price, and the impact of HPV diseases on quality of life. CONCLUSIONS: Mid-adult vaccination is much less cost-effective than the comparison strategy of routine vaccination for all adolescents at ages 11 to 12 years and catch-up vaccination for women through age 26 years and men through age 21 years.
引用
- Chesson HW, Meites E, Ekwueme DU, et al. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model. Vaccine. 2020. PMID: 33121846. doi:10.1016/j.vaccine.2020.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。